Protective Effects of Lovastatin in a Population‐Based ALS Study and Mouse Model
Annals of Neurology · 2023
DOI: 10.1002/ana.26600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, 2023. Verfasst von Collin J Kreple und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Washington University School of Medicine, St. Louis, MO. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Motor Neuron Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, NINDS NIH HHS, ALS Association.
Abstract (Originalsprache)
Objective
The objective of this study was to use a novel combined pharmacoepidemiologic and amyotrophic lateral sclerosis (ALS) mouse model approach to identify potential motor neuron protective medications.
Methods
We constructed a large, population‐based case‐control study to investigate motor neuron disease (MND) among US Medicare beneficiaries aged 66 to 90 in 2009. We included 1,128 incident MND cases and 56,400 age, sex, race, and ethnicity matched controls. We calculated MND relative risk for >1,000 active ingredients represented in Part D (pharmacy) claims in 2006 to 2007 (>1 year before diagnosis/reference). We then applied a comprehensive screening approach to select medications for testing in SOD1 G93A mice: sulfasalazine, telmisartan, and lovastatin. We treated mice with the human dose equivalent of the medication or vehicle via subcutaneous osmotic pump before onset of weakness. We then assessed weight, gait, and survival. In additional mice, we conducted histological studies.
Results
We observed previously established medical associations for MND and an inverse dose–response association between lovastatin and MND, with 28% reduced risk at 40 mg/day. In SOD1 G93A mouse studies, sulfasalazine and telmisartan conferred no benefit, whereas lovastatin treatment delayed onset and prolonged survival. Lovastatin treated mice also had less microgliosis, misfolded SOD1, and spinal motor neuron loss in the ventral horn.
Interpretation
Lovastatin reduced the risk of ALS in humans, which was confirmed in an ALS mouse model by delayed symptom onset, prolonged survival, and preservation of motor neurons. Although further studies to understand the mechanism are required, lovastatin may represent a potential neuroprotective therapy for patients with ALS. These data demonstrate the utility of a combined pharmacoepidemiologic and mouse model approach. ANN NEUROL 2023;93:881–892
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Washington University School of Medicine, St. Louis, MO.
- Barrow Neurological Institute, Phoenix, AZ.
- School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Parktown, South Africa.
ORCID-Profile: Timothy M Miller
Förderung
- NIEHS NIH HHS
- NINDS NIH HHS
- ALS Association
- American Academy of Neurology
- American Brain Foundation
- Children's Discovery Institute
- Hope Center for Neurological Disorders
- Michael J. Fox Foundation for Parkinson's Research
Zitieren
APA
Kreple, C. J., Searles Nielsen, S., Schoch, K. M., Shen, T., Shabsovich, M., Song, Y., Racette, B. A., & Miller, T. M. (2023). Protective Effects of Lovastatin in a Population‐Based ALS Study and Mouse Model. Annals of Neurology. https://doi.org/10.1002/ana.26600
Vancouver
Kreple CJ, Searles Nielsen S, Schoch KM, Shen T, Shabsovich M, Song Y, et al. Protective Effects of Lovastatin in a Population‐Based ALS Study and Mouse Model. Annals of Neurology. 2023. doi:10.1002/ana.26600
BibTeX
@article{Kreple2023,
author = {Kreple, Collin J and Searles Nielsen, Susan and Schoch, Kathleen M and Shen, Tao and Shabsovich, Mark and Song, Yizhe and Racette, Brad A and Miller, Timothy M},
title = {Protective Effects of Lovastatin in a Population‐Based ALS Study and Mouse Model},
journal = {Annals of Neurology},
year = {2023},
doi = {10.1002/ana.26600}
}
EUVIMED